Form 4: Ocular Therapeutix Executive Chairman, President, and CEO Receives Stock Grants

Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, receives restricted stock units (RSUs) and performance stock units (PSUs) under the company's 2021 Stock Incentive Plan.

Summary

• Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, was granted 1,250,000 restricted stock units (RSUs) and 1,500,000 performance stock units (PSUs) on February 11, 2025.
• The RSUs vest over three years, with one-third vesting annually starting on the first anniversary of the grant date, subject to continued service.
• The PSUs can be earned over a five-year period based on the achievement of share price hurdles: $15.00, $20.00, $25.00, and $30.00 per share.
• PSUs vest upon achieving the share price hurdle or the three-year anniversary of the grant date, whichever is later, also subject to continued service.
• The reporting person's total holdings after the transaction are 2,041,793 shares held directly and 3,541,793 shares held directly.

Sentiment

Score: 7

Explanation: The document is a standard SEC filing detailing executive compensation. It's neutral to slightly positive as it indicates continued investment in the company's leadership.

Positives

• The grant of RSUs and PSUs aligns the executive's interests with those of the shareholders.
• The performance-based vesting of PSUs incentivizes the executive to drive share price appreciation.

Risks

• The executive must remain in service for the RSUs and PSUs to fully vest.
• The PSUs may not vest if the share price targets are not met.

Future Outlook

The vesting of the PSUs is dependent on the future share price performance of Ocular Therapeutix.

Industry Context

Stock grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• Shareholders may view the stock grants as a positive sign, aligning management's interests with the company's success.
• Employees may see the grants as a sign of confidence in the company's future.

Key Dates

Keywords

Ocular Therapeutix, Pravin Dugel, RSU, PSU, Stock Incentive Plan, Executive Compensation, Share Price Hurdle, Vesting